Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
Authors
Keywords
-
Journal
Biomed Research International
Volume 2015, Issue -, Pages 1-17
Publisher
Hindawi Limited
Online
2015-11-17
DOI
10.1155/2015/341430
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Drug resistance-related microRNAs in hematological malignancies: Translating basic evidence into therapeutic strategies
- (2015) Lingling Xie et al. BLOOD REVIEWS
- The development of potential antibody-based therapies for myeloma
- (2015) Daniel W. Sherbenou et al. BLOOD REVIEWS
- Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma
- (2015) J. F. San Miguel et al. HAEMATOLOGICA
- The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study
- (2015) H Suen et al. LEUKEMIA
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma
- (2015) J. F. San Miguel et al. HAEMATOLOGICA
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
- (2014) Y. X. Zhu et al. BLOOD
- Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells
- (2014) J. Chu et al. CLINICAL CANCER RESEARCH
- MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib
- (2014) S Jagannathan et al. LEUKEMIA
- Carfilzomib: A Second-Generation Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
- (2013) Jennifer L Thompson ANNALS OF PHARMACOTHERAPY
- High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
- (2013) Daniel Heintel et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma
- (2013) Jonathan L. Kaufman et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma
- (2013) Peter M. Voorhees et al. BRITISH JOURNAL OF HAEMATOLOGY
- Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth
- (2013) E. Leone et al. CLINICAL CANCER RESEARCH
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease
- (2013) R. Kurzrock et al. CLINICAL CANCER RESEARCH
- Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges
- (2013) Ethan Q Han et al. Journal of Hematology & Oncology
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
- (2013) Jesus San Miguel et al. LANCET ONCOLOGY
- Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma
- (2013) D Atanackovic et al. LEUKEMIA
- MicroRNA theragnostics for the clinical management of multiple myeloma
- (2013) N Ahmad et al. LEUKEMIA
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
- (2013) J Chu et al. LEUKEMIA
- Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma
- (2013) Jason M Steele JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma
- (2012) Dehui Xu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma
- (2012) S. Blotta et al. BLOOD
- Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
- (2012) P. G. Richardson et al. BLOOD
- High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance
- (2012) A. Broyl et al. BLOOD
- Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma
- (2012) D. J. Kuhn et al. BLOOD
- A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma
- (2012) William Bensinger et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance
- (2012) Dharminder Chauhan et al. CANCER CELL
- p38 MAPK in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction
- (2012) J. He et al. CANCER RESEARCH
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
- (2012) A Lopez-Girona et al. LEUKEMIA
- Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma
- (2012) H Tamura et al. LEUKEMIA
- FcRL5 as a Target of Antibody-Drug Conjugates for the Treatment of Multiple Myeloma
- (2012) K. Elkins et al. MOLECULAR CANCER THERAPEUTICS
- Latest advances and current challenges in the treatment of multiple myeloma
- (2012) Anuj Mahindra et al. Nature Reviews Clinical Oncology
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial
- (2011) Shaji K. Kumar et al. AMERICAN JOURNAL OF HEMATOLOGY
- Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1
- (2011) Yi-Kun Zhang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade
- (2011) William H.D. Hallett et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
- (2011) J. D. Shaughnessy et al. BLOOD
- Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies
- (2011) N. Korde et al. BLOOD
- A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
- (2011) J. A. Zonder et al. BLOOD
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
- (2011) Y. X. Zhu et al. BLOOD
- Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications
- (2011) Douglas W. McMillin et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response
- (2011) Antonia Lopez-Girona et al. BRITISH JOURNAL OF HAEMATOLOGY
- Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study
- (2011) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Deregulated microRNAs in multiple myeloma
- (2011) Leonidas Benetatos et al. CANCER
- miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma
- (2011) Lijuan Chen et al. CANCER LETTERS
- In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells
- (2011) Dharminder Chauhan et al. CLINICAL CANCER RESEARCH
- Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial
- (2011) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study
- (2011) Irene M Ghobrial et al. LANCET ONCOLOGY
- Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma
- (2011) P Moreau et al. LEUKEMIA
- MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma
- (2011) V Ramakrishnan et al. LEUKEMIA
- Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation
- (2011) Xudong Wang et al. LEUKEMIA & LYMPHOMA
- Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
- (2011) T. Hideshima et al. MOLECULAR CANCER THERAPEUTICS
- Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin
- (2010) Gabriele Buda et al. ANNALS OF HEMATOLOGY
- A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma
- (2010) D. Chauhan et al. BLOOD
- A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma
- (2010) G. Gorgun et al. BLOOD
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
- (2010) P. G. Richardson et al. BLOOD
- Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor
- (2010) B. Jena et al. BLOOD
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo
- (2010) Ajita V. Singh et al. BRITISH JOURNAL OF HAEMATOLOGY
- MicroRNA and drug resistance
- (2010) J Ma et al. CANCER GENE THERAPY
- A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma
- (2010) M. Hussein et al. HAEMATOLOGICA
- MicroRNA 125b inhibition of B cell differentiation in germinal centers
- (2010) Murali Gururajan et al. INTERNATIONAL IMMUNOLOGY
- Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer
- (2010) Marc Cartellieri et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
- (2010) Maria-Victoria Mateos et al. JOURNAL OF CLINICAL ONCOLOGY
- Reiterative Survival Analyses of Total Therapy 2 for Multiple Myeloma Elucidate Follow-Up Time Dependency of Prognostic Variables and Treatment Arms
- (2010) Bart Barlogie et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone
- (2010) H Avet-Loiseau et al. LEUKEMIA
- Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF
- (2010) Michael Quigley et al. NATURE MEDICINE
- Targeting cancer stem cells by inhibiting Wnt, Notch and Hedgehog pathways
- (2010) Naoko Takebe et al. Nature Reviews Clinical Oncology
- High-risk myeloma is associated with global elevation of miRNAs and overexpression ofEIF2C2/AGO2
- (2010) Yiming Zhou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034): Table 1
- (2009) H. Miles Prince et al. BLOOD
- CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
- (2009) A. K. Azab et al. BLOOD
- A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
- (2009) H. M. Lokhorst et al. BLOOD
- MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma
- (2009) A. M. Roccaro et al. BLOOD
- Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
- (2009) F. Parlati et al. BLOOD
- The Role of ATF4 Stabilization and Autophagy in Resistance of Breast Cancer Cells Treated with Bortezomib
- (2009) M. Milani et al. CANCER RESEARCH
- Genomic Screening for Genes Silenced by DNA Methylation Revealed an Association between RASD1 Inactivation and Dexamethasone Resistance in Multiple Myeloma
- (2009) M. Nojima et al. CLINICAL CANCER RESEARCH
- Importance of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in Intratumoral Disposition of Anticancer Agents
- (2009) B. Rochat CURRENT CANCER DRUG TARGETS
- Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
- (2009) T. Wilson et al. CURRENT CANCER DRUG TARGETS
- A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients
- (2009) Klaudia Kuranda et al. EXPERIMENTAL HEMATOLOGY
- PD-1 signaling in primary T cells
- (2009) James L. Riley IMMUNOLOGICAL REVIEWS
- Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
- (2009) Cyrille Hulin et al. JOURNAL OF CLINICAL ONCOLOGY
- Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
- (2009) Martha Q. Lacy et al. JOURNAL OF CLINICAL ONCOLOGY
- MicroRNAs in Cancer: Small Molecules With a Huge Impact
- (2009) Marilena V. Iorio et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma
- (2008) A. Palumbo et al. ANNALS OF ONCOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis
- (2008) Patricia Balsas et al. BIOCHEMICAL PHARMACOLOGY
- Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma
- (2008) H. Ludwig et al. BLOOD
- Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
- (2008) B. Barlogie et al. BLOOD
- Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
- (2008) A. Palumbo et al. BLOOD
- An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma
- (2008) Domenica Ronchetti et al. BMC Medical Genomics
- p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications
- (2008) Kenji Ishitsuka et al. BRITISH JOURNAL OF HAEMATOLOGY
- Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance
- (2008) W. Matsui et al. CANCER RESEARCH
- The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma
- (2008) Philipp Baumann et al. EXPERIMENTAL CELL RESEARCH
- Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma
- (2008) Martha Q. Lacy et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma
- (2008) S. Vincent Rajkumar et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiple Myeloma Cancer Stem Cells
- (2008) Carol Ann Huff et al. JOURNAL OF CLINICAL ONCOLOGY
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
- (2008) R A Kyle et al. LEUKEMIA
- IRF4 addiction in multiple myeloma
- (2008) Arthur L. Shaffer et al. NATURE
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nucleoside analogs: molecular mechanisms signaling cell death
- (2008) B Ewald et al. ONCOGENE
- MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis
- (2008) F. Pichiorri et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started